Jorge Caicedo (J Caicedo)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 7

Top Topics

Atrial Fibrillation

Ejection Fraction

Pain Management

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

Expert review of hematology

Journal of medical economics

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia 29 (3) (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia 29 (3) (2023)
Miguel A Escobar, Neha Agrawal, Sagnik Chatterjee, Swastik Bhattacharya, Jorge Caicedo, Michael Bullano, Bob G Schultz
Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors. Journal of medical economics (2023)
Miguel A Escobar, Michael Bullano, Ali G Mokdad, Jorge Caicedo, Bob G Schultz, Qi Fan, Sumit Verma
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert review of hematology (2023)
Nathan T Connell, Jorge Caicedo, N Nieto, Sagnik Chatterjee, A Hait, A K Gupta, Michael Bullano, Bob G Schultz
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia. Expert review of pharmacoeconomics & outcomes research (2023)
Katharine Batt, Bob G Schultz, Jorge Caicedo, Christopher S Hollenbeak, Neha Agrawal, Sagnik Chatterjee, Michael Bullano
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Current medical research and opinion 38 (10) (2022)